Unknown

Dataset Information

0

Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer.


ABSTRACT: HER2-targeted therapy has been shown to have limited efficacy in ovarian cancer despite frequent overexpression of this receptor. Photochemical internalization (PCI) is a modality for cytosolic drug delivery, currently undergoing clinical evaluation. In the present project we studied the application of PCI in combination with the HER2-targeted recombinant fusion toxin, MH3-B1/rGel, for the treatment of ovarian cancer. The SKOV-3 cell line, resistant to trastuzumab- and MH3-B1/rGel- monotherapy, was shown to respond strongly to PCI of MH3-B1/rGel to a similar extent as observed for the treatment-sensitive SK-BR-3 breast cancer cells. Extensive hydrolytic degradation of MH3-B1/rGel in acidic endocytic vesicles was indicated as the mechanism of MH3-B1/rGel resistance in SKOV-3 cells. This was shown by the positive Pearson's correlation coefficient between Alexa488-labeled MH3-B1/rGel and Lysotracker in SKOV-3 cells in contrast to the negative Pearson's correlation coefficient in SK-BR-3 cells. The application of PCI to induce the release of MH3-B1/rGel was also demonstrated to be effective on SKOV-3 xenografts. Application of PCI with MH3-B1/rGel was further found highly effective in the HER2 expressing HOC-7 and NuTu-19 ovarian cancer cell lines. The presented results warrant future development of PCI in combination with MH3-B1/rGel as a novel therapeutic approach in preclinical models of ovarian cancer.

SUBMITTER: Bull-Hansen B 

PROVIDER: S-EPMC4494949 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer.

Bull-Hansen Bente B   Berstad Maria B MB   Berg Kristian K   Cao Yu Y   Skarpen Ellen E   Fremstedal Ane Sofie AS   Rosenblum Michael G MG   Peng Qian Q   Weyergang Anette A  

Oncotarget 20150501 14


HER2-targeted therapy has been shown to have limited efficacy in ovarian cancer despite frequent overexpression of this receptor. Photochemical internalization (PCI) is a modality for cytosolic drug delivery, currently undergoing clinical evaluation. In the present project we studied the application of PCI in combination with the HER2-targeted recombinant fusion toxin, MH3-B1/rGel, for the treatment of ovarian cancer. The SKOV-3 cell line, resistant to trastuzumab- and MH3-B1/rGel- monotherapy,  ...[more]

Similar Datasets

| S-EPMC9218503 | biostudies-literature
| S-EPMC8379900 | biostudies-literature
| S-EPMC6376473 | biostudies-literature
| S-EPMC3263614 | biostudies-literature
| S-EPMC6448105 | biostudies-literature
| S-EPMC6439986 | biostudies-literature
| S-EPMC6223341 | biostudies-literature
| S-EPMC10189780 | biostudies-literature
| S-EPMC3070817 | biostudies-literature
| S-EPMC3267001 | biostudies-literature